
[Federal Register: October 5, 2010 (Volume 75, Number 192)]
[Notices]               
[Page 61501-61502]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05oc10-111]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0496]

 
Cooperative Agreement To Support Capacity Building Activities 
Through the World Health Organization Global Foodborne Infections 
Network

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
intention to accept and consider a single source application to award a 
cooperative agreement to the World Health Organization (WHO) Advisory 
Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) 
and in support of the WHO Global Foodborne Infections Network (GFN) and 
to provide guidance to the WHO on a framework for the development of an 
international network to promote and enhance collaboration on 
harmonization and data sharing among countries with Antimicrobial 
Resistance (AMR) surveillance programs.

FOR FURTHER INFORMATION AND ADDITIONAL REQUIREMENTS CONTACT:
    Program Contact: Patrick McDermott, Division of Animal and Food 
Microbiology, Center for Veterinary Medicine, Food and Drug 
Administration, 7519 Standish Pl., Mod II, rm. 1505, Rockville, MD 
20855, 301-210-4213, FAX: 301-210-4685, email: 
Patrick.McDermott@fda.hhs.gov.
    Management Contact: Katherine C. Bond, Office of International 
Programs, Office of the Commissioner, FDA, White Oak Bldg. 32, rm. 
3300, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-8318, 
FAX: 301-595-5058, email: Katherine.Bond@fda.hhs.gov.
    Grants Contact: Kimberly Pendleton, Division of Acquisition and 
Grants, FDA, 5630 Fishers Lane (HFA-500), rm. 2104, Rockville, MD 
20857, 301-827-9363, FAX: 301-827-7101, email: 
kimberly.pendleton@fda.hhs.gov.
    For more information on this funding opportunity announcement (FOA) 
and to obtain detailed requirements, please contact Kimberly Pendleton.

SUPPLEMENTARY INFORMATION:

I. Funding Opportunity Description

[RFA-FD-10-006]
[Catalog of Federal Domestic Assistance Number(s): 93.103 https://
www.cfda.gov]

A. Background

    The Food and Drug Administration (FDA) is announcing its intention 
to accept and consider a single source application for a cooperative 
agreement to the WHO GFN. This project represents a collaborative 
agreement between the WHO and FDA aimed at capacity building in 
laboratory based surveillance of foodborne pathogens and disease in 
developing regions to support AGISAR and GFN to enable FDA to realize 
its goal of developing an international database for human and animal 
isolates of foodborne pathogens and their susceptibility profiles.

B. Research Objectives

     Support WHO capacity building activities with member 
countries for AMR monitoring (development of AMR training modules for 
GFN training courses, and hosting of visiting scientist from developing 
countries).
     Develop harmonized schemes for monitoring antimicrobial 
resistance in zoonotic and enteric bacteria to include appropriate 
sampling.
     Promote information sharing on AMR (development of a 
global AMR databank).
     Provide expert advice to WHO, and promote WHO and FDA 
collaborative work to advise WHO Member States on containment of AMR 
with a particular focus to Human Critically Important Antimicrobials. 
AGISAR should be the core advisory group to review criteria for ranking 
human and animal antimicrobials to be reviewed by WHO; and FDA's 
resources could be used in support of AGISAR's participation.
     Support and advise WHO on selection of sentinel sites to 
be strategically identified around the globe and designing pilot 
projects to conduct integrated surveillance of antimicrobial 
resistance.
     Promote development of standardized methods for monitoring 
antimicrobial use and work with member states for the implementation of 
these methods at the country-level.
     Promote the development of published articles on the 
emergence of AMR threats and challenges, and the

[[Page 61502]]

need for AMR surveillance with a forward-look toward sustainable 
solutions through global collaboration and evidence-based approaches.

C. Eligibility Information

    The following organizations/institutions are eligible to apply: The 
World Health Organization

II. Award Information/Funds Available

A. Award Amount

    FDA anticipates providing one award of $847,500 (total costs 
including indirect costs) in fiscal year (FY) 2010 in support of this 
project. Subject to the availability of funds and successful 
performance, 2 additional years of support up to $565,000 per year will 
be available.

B. Length of Support

    The support will be 1 year with the possibility of an additional 2 
years of noncompetitive support. Continuation beyond the first year 
will be based on satisfactory performance during the preceding year, 
receipt of a non-competing continuation application and available 
Federal FY appropriations.

    Dated: September 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-24903 Filed 10-4-10; 8:45 am]
BILLING CODE 4160-01-S

